The company has one of the earliest teams in China to develop nucleic acid drug production processes and conduct CMC research. It has been deeply involved in the field of nucleic acid drugs for more than ten years and has the richest experience in project development and product registration in the industry. At present, the company has established a leading oligonucleotide drug CDMO platform in the industry, with mature process development and production flow system, and has carried out in-depth cooperation with multiple domestic and foreign pharmaceutical and biotechnology companies.